^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
etakafusp alfa (AB248)
i
Other names: AB248, AB-248
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Asher Biotherap
Drug class:
IL-2 stimulant, CD8 T-cell agonist
Related drugs:
2ms
A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) (clinicaltrials.gov)
P1, N=380, Recruiting, Amgen | Not yet recruiting --> Recruiting
Enrollment open
|
Imdelltra (tarlatamab-dlle) • etakafusp alfa (AB248)
3ms
KEYNOTE-E29: A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors (clinicaltrials.gov)
P1, N=552, Active, not recruiting, Asher Biotherapeutics, Inc. | Recruiting --> Active, not recruiting
Enrollment closed
|
Keytruda (pembrolizumab) • etakafusp alfa (AB248)
5ms
A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) (clinicaltrials.gov)
P1, N=380, Not yet recruiting, Amgen
New P1 trial
|
Imdelltra (tarlatamab-dlle) • etakafusp alfa (AB248)
over1year
KEYNOTE-E29: A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors (clinicaltrials.gov)
P1, N=462, Recruiting, Asher Biotherapeutics, Inc. | N=262 --> 462 | Trial completion date: Oct 2025 --> May 2027 | Trial primary completion date: Jun 2025 --> Aug 2026
Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • etakafusp alfa (AB248)
over1year
IL-2 targeted to CD8+ T cells promotes robust effector T cell responses and potent antitumor immunity. (PubMed, Cancer Discov)
Efficacy was associated with expansion and phenotypic enhancement of tumor-infiltrating CD8+ T cells, including the emergence of a "better effector" population. These data support the potential utility of AB248 in clinical settings.
Journal
|
CD8 (cluster of differentiation 8) • IL2 (Interleukin 2)
|
etakafusp alfa (AB248)
almost2years
KEYNOTE-E29: A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors (clinicaltrials.gov)
P1, N=262, Recruiting, Asher Biotherapeutics, Inc.
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • etakafusp alfa (AB248)
2years
KEYNOTE-E29: A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors (clinicaltrials.gov)
P1, N=262, Recruiting, Asher Biotherapeutics, Inc. | Phase classification: P1a/1b --> P1
Phase classification • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • etakafusp alfa (AB248)
over2years
An open-label, phase 1a/b study of AB248, a CD8+ selective IL-2 mutein fusion protein, alone or in combination with pembrolizumab in patients with advanced solid tumors (AACR 2023)
Adverse events will be assessed by CTCAE v5.0. The study is currently open for enrollment in the dose escalation phase at multiple sites in the US.
Clinical • P1 data • Combination therapy • PD(L)-1 Biomarker • IO biomarker • Metastases
|
CD8 (cluster of differentiation 8) • IL2 (Interleukin 2)
|
Keytruda (pembrolizumab) • etakafusp alfa (AB248)
almost3years
A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors (clinicaltrials.gov)
P1a/1b, N=262, Recruiting, Asher Biotherapeutics, Inc. | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy • Metastases
|
CD8 (cluster of differentiation 8)
|
Keytruda (pembrolizumab) • etakafusp alfa (AB248)
almost3years
A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors (clinicaltrials.gov)
P1a/1b, N=262, Not yet recruiting, Asher Biotherapeutics, Inc.
New P1 trial • Combination therapy • Metastases
|
CD8 (cluster of differentiation 8)
|
Keytruda (pembrolizumab) • etakafusp alfa (AB248)
Share via
